Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ROIV |
---|---|---|
09:32 ET | 209621 | 11.56 |
09:34 ET | 12243 | 11.55 |
09:36 ET | 3388 | 11.564 |
09:38 ET | 113833 | 11.58 |
09:39 ET | 13631 | 11.56 |
09:41 ET | 24550 | 11.565 |
09:43 ET | 9377 | 11.555 |
09:45 ET | 25798 | 11.575 |
09:48 ET | 14946 | 11.565 |
09:50 ET | 16966 | 11.545 |
09:52 ET | 12040 | 11.555 |
09:54 ET | 46425 | 11.54 |
09:56 ET | 7624 | 11.51 |
09:57 ET | 7760 | 11.5 |
09:59 ET | 23531 | 11.5 |
10:01 ET | 29585 | 11.53 |
10:03 ET | 8173 | 11.495 |
10:06 ET | 18252 | 11.5 |
10:08 ET | 19073 | 11.485 |
10:10 ET | 15086 | 11.495 |
10:12 ET | 31839 | 11.505 |
10:14 ET | 74558 | 11.475 |
10:15 ET | 26800 | 11.48 |
10:17 ET | 62090 | 11.505 |
10:19 ET | 22640 | 11.48 |
10:21 ET | 9308 | 11.5 |
10:24 ET | 16895 | 11.5 |
10:26 ET | 7561 | 11.52 |
10:28 ET | 7697 | 11.5 |
10:30 ET | 11980 | 11.5 |
10:32 ET | 33218 | 11.505 |
10:33 ET | 12240 | 11.515 |
10:35 ET | 41912 | 11.53 |
10:37 ET | 21168 | 11.525 |
10:39 ET | 4183 | 11.53 |
10:42 ET | 14663 | 11.525 |
10:44 ET | 10327 | 11.545 |
10:46 ET | 7861 | 11.545 |
10:48 ET | 4674 | 11.55 |
10:50 ET | 38342 | 11.52 |
10:51 ET | 6638 | 11.51 |
10:53 ET | 8708 | 11.5 |
10:55 ET | 60009 | 11.5 |
10:57 ET | 17766 | 11.505 |
11:00 ET | 5366 | 11.505 |
11:02 ET | 25373 | 11.5 |
11:04 ET | 6050 | 11.5 |
11:06 ET | 6310 | 11.505 |
11:08 ET | 44378 | 11.5 |
11:09 ET | 20513 | 11.465 |
11:11 ET | 3489 | 11.465 |
11:13 ET | 9648 | 11.465 |
11:15 ET | 74084 | 11.48 |
11:18 ET | 2176 | 11.47 |
11:20 ET | 7696 | 11.445 |
11:22 ET | 4485 | 11.445 |
11:24 ET | 12360 | 11.465 |
11:26 ET | 43564 | 11.485 |
11:27 ET | 11254 | 11.49 |
11:29 ET | 18651 | 11.49 |
11:31 ET | 4493 | 11.485 |
11:33 ET | 14202 | 11.5 |
11:36 ET | 21868 | 11.5 |
11:38 ET | 7542 | 11.495 |
11:40 ET | 29708 | 11.495 |
11:42 ET | 6513 | 11.505 |
11:44 ET | 1542 | 11.51 |
11:45 ET | 66082 | 11.5 |
11:47 ET | 86702 | 11.495 |
11:49 ET | 5819 | 11.49 |
11:51 ET | 13941 | 11.495 |
11:54 ET | 13231 | 11.495 |
11:56 ET | 20874 | 11.48 |
11:58 ET | 5802 | 11.47 |
12:00 ET | 21114 | 11.475 |
12:02 ET | 20485 | 11.485 |
12:03 ET | 5703 | 11.495 |
12:05 ET | 23535 | 11.5 |
12:07 ET | 14112 | 11.505 |
12:09 ET | 9883 | 11.5 |
12:12 ET | 3083 | 11.505 |
12:14 ET | 3824 | 11.505 |
12:16 ET | 12957 | 11.505 |
12:18 ET | 1800 | 11.505 |
12:20 ET | 19844 | 11.5 |
12:21 ET | 16242 | 11.495 |
12:23 ET | 5280 | 11.495 |
12:25 ET | 19264 | 11.485 |
12:27 ET | 9835 | 11.485 |
12:30 ET | 21380 | 11.495 |
12:32 ET | 4297 | 11.5 |
12:34 ET | 23366 | 11.495 |
12:36 ET | 18645 | 11.51 |
12:38 ET | 7493 | 11.51 |
12:39 ET | 13087 | 11.495 |
12:41 ET | 30134 | 11.47 |
12:43 ET | 3324 | 11.475 |
12:45 ET | 7617 | 11.47 |
12:48 ET | 9703 | 11.46 |
12:50 ET | 15639 | 11.465 |
12:52 ET | 4510 | 11.47 |
12:54 ET | 14684 | 11.48 |
12:56 ET | 95302 | 11.5 |
12:57 ET | 25182 | 11.485 |
12:59 ET | 1321 | 11.485 |
01:01 ET | 8142 | 11.48 |
01:03 ET | 29532 | 11.4749 |
01:06 ET | 21174 | 11.475 |
01:08 ET | 13921 | 11.465 |
01:10 ET | 13520 | 11.4743 |
01:12 ET | 18283 | 11.475 |
01:14 ET | 7799 | 11.465 |
01:15 ET | 9117 | 11.45 |
01:17 ET | 5766 | 11.445 |
01:19 ET | 3583 | 11.445 |
01:21 ET | 14474 | 11.435 |
01:24 ET | 7307 | 11.425 |
01:26 ET | 16464 | 11.405 |
01:28 ET | 22101 | 11.39 |
01:30 ET | 5290 | 11.4 |
01:32 ET | 18288 | 11.4 |
01:33 ET | 44051 | 11.404 |
01:35 ET | 5315 | 11.405 |
01:37 ET | 14308 | 11.3858 |
01:39 ET | 14230 | 11.39 |
01:42 ET | 3315 | 11.385 |
01:44 ET | 1450 | 11.385 |
01:46 ET | 33349 | 11.395 |
01:48 ET | 8179 | 11.4 |
01:50 ET | 2925 | 11.405 |
01:51 ET | 10334 | 11.405 |
01:53 ET | 4446 | 11.405 |
01:55 ET | 2954 | 11.405 |
01:57 ET | 10074 | 11.415 |
02:00 ET | 31702 | 11.42 |
02:02 ET | 2674 | 11.425 |
02:04 ET | 34912 | 11.435 |
02:06 ET | 10525 | 11.42 |
02:08 ET | 2100 | 11.42 |
02:09 ET | 8744 | 11.42 |
02:11 ET | 1405 | 11.42 |
02:13 ET | 3470 | 11.425 |
02:15 ET | 3811 | 11.425 |
02:18 ET | 25478 | 11.435 |
02:20 ET | 10553 | 11.425 |
02:22 ET | 16174 | 11.44 |
02:24 ET | 1300 | 11.445 |
02:26 ET | 15034 | 11.44 |
02:27 ET | 3727 | 11.445 |
02:29 ET | 6155 | 11.455 |
02:31 ET | 25889 | 11.455 |
02:33 ET | 17112 | 11.465 |
02:36 ET | 7265 | 11.45 |
02:38 ET | 1842 | 11.455 |
02:40 ET | 20682 | 11.44 |
02:42 ET | 3118 | 11.44 |
02:44 ET | 4933 | 11.445 |
02:45 ET | 45900 | 11.455 |
02:47 ET | 3449 | 11.455 |
02:49 ET | 5830 | 11.455 |
02:51 ET | 9293 | 11.45 |
02:54 ET | 5607 | 11.445 |
02:56 ET | 15364 | 11.45 |
02:58 ET | 19038 | 11.465 |
03:00 ET | 2589 | 11.46 |
03:02 ET | 1600 | 11.465 |
03:03 ET | 40904 | 11.44 |
03:05 ET | 22849 | 11.465 |
03:07 ET | 22873 | 11.45 |
03:09 ET | 3949 | 11.455 |
03:12 ET | 3300 | 11.45 |
03:14 ET | 22114 | 11.44 |
03:16 ET | 5562 | 11.445 |
03:18 ET | 42762 | 11.43 |
03:20 ET | 4339 | 11.435 |
03:21 ET | 21612 | 11.425 |
03:23 ET | 38887 | 11.42 |
03:25 ET | 3866 | 11.425 |
03:27 ET | 14629 | 11.425 |
03:30 ET | 2396 | 11.425 |
03:32 ET | 37311 | 11.4 |
03:34 ET | 29211 | 11.39 |
03:36 ET | 20052 | 11.39 |
03:38 ET | 34114 | 11.365 |
03:39 ET | 21261 | 11.375 |
03:41 ET | 21481 | 11.375 |
03:43 ET | 62080 | 11.385 |
03:45 ET | 13457 | 11.38 |
03:48 ET | 49361 | 11.375 |
03:50 ET | 72723 | 11.3887 |
03:52 ET | 110085 | 11.35 |
03:54 ET | 15426 | 11.34 |
03:56 ET | 270248 | 11.355 |
03:57 ET | 100603 | 11.365 |
03:59 ET | 1080923 | 11.37 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Roivant Sciences Ltd | 8.5B | 2.0x | --- |
Corcept Therapeutics Inc | 4.8B | 41.1x | +9.80% |
Ligand Pharmaceuticals Inc | 1.8B | 45.6x | -12.71% |
Harrow Inc | 1.6B | -46.8x | --- |
Ocular Therapeutix Inc | 1.4B | -8.3x | --- |
Immunocore Holdings PLC | 1.6B | -29.2x | --- |
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 for the treatment of dermatomyositis and non-infectious uveitis, in addition to other clinical-stage molecules. It advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its pipeline program also includes Mosliciguat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.5B |
---|---|
Revenue (TTM) | $158.3M |
Shares Outstanding | 739.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $5.57 |
Book Value | $7.40 |
P/E Ratio | 2.0x |
Price/Sales (TTM) | 53.9 |
Price/Cash Flow (TTM) | 1.8x |
Operating Margin | 2,799.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.